H. Lundbeck A Logo

H. Lundbeck A

Develops and commercializes innovative therapeutics for brain diseases globally.

HLUN | CO

Overview

Corporate Details

ISIN(s):
DK0061804697 (+5 more)
LEI:
5493006R4KC2OI5D3470
Country:
Denmark
Address:
Ottiliavej 9, 2500 Valby
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

H. Lundbeck A/S is a global pharmaceutical company dedicated exclusively to developing and commercializing innovative treatments for brain diseases. The company's core focus is on neuroscience, engaging in the full value chain of research, development, manufacturing, and sales of therapeutics for psychiatric and neurological disorders. Its portfolio addresses a variety of conditions, including depression, migraine, and rare epilepsies. With a mission to advance brain health, Lundbeck markets its specialized products in numerous countries worldwide, managing operations from initial research to patient delivery.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-11-14 14:51
Regulatory Filings
English 96.8 KB
2025-11-14 12:45
M&A Activity
English 25.3 KB
2025-11-14 12:45
Regulatory Filings
English 96.8 KB
2025-11-11 15:22
Regulatory Filings
English 116.4 KB
2025-11-11 15:22
Earnings Release
English 24.6 KB
2025-09-20 08:00
Regulatory Filings
English 146.2 KB
2025-09-20 08:00
Legal Proceedings Report
English 30.0 KB
2025-08-13 18:41
Interim / Quarterly Report
English 1.0 MB
2025-08-13 18:41
Earnings Release
English 32.1 KB
2025-08-13 18:35
Earnings Release
English 24.2 KB
2025-08-13 18:35
Earnings Release
English 129.5 KB
2025-02-21 13:27
Director's Dealing
English 124.1 KB
2025-02-21 13:27
Director's Dealing
English 29.9 KB
2025-02-05 16:40
Director's Dealing
English 134.1 KB
2025-02-05 16:40
Director's Dealing
English 96.6 KB

Automate Your Workflow. Get a real-time feed of all H. Lundbeck A filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for H. Lundbeck A

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for H. Lundbeck A via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Access Bio, Inc. Logo
Develops and manufactures rapid diagnostic tests for infectious diseases for global health.
United States of America
950130
ACHIEVE LIFE SCIENCES, INC. Logo
Developing cytisinicline, a plant-based treatment for smoking cessation and nicotine addiction.
United States of America
ACHV
AC Immune SA Logo
Developing precision medicine to diagnose, treat, and prevent neurodegenerative diseases.
United States of America
ACIU
Aclaris Therapeutics, Inc. Logo
A clinical-stage biopharma developing novel drugs for immuno-inflammatory diseases.
United States of America
ACRS
Acrivon Therapeutics, Inc. Logo
Develops precision cancer therapies by matching patients to drugs using its proteomics platform.
United States of America
ACRV
Acticor Biotech Logo
Clinical-stage biopharma developing a first-in-class drug for thrombotic diseases like stroke.
France
ALACT
Actinium Pharmaceuticals, Inc. Logo
Develops targeted radiotherapies for advanced cancers like AML and prostate cancer.
United States of America
ATNM
ACTUATE THERAPEUTICS, INC. Logo
Clinical-stage biopharma developing a novel GSK-3 inhibitor for hard-to-treat cancers.
United States of America
ACTU
AcuCort AB Logo
Develops a rapid oral film for acute allergies, croup, and chemo-induced nausea.
Sweden
ACUC
Acumen Pharmaceuticals, Inc. Logo
Clinical-stage biopharma developing an antibody therapy for Alzheimer's by targeting toxic AβOs.
United States of America
ABOS

Talk to a Data Expert

Have a question? We'll get back to you promptly.